Published in Ann Rheum Dis on February 04, 2005
Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis (2006) 2.68
Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum (2008) 1.48
Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis (2005) 1.29
Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol (2006) 1.18
Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis (2007) 1.11
Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis (2005) 1.06
Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis (2006) 1.01
Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance. Curr Rheumatol Rep (2011) 0.95
The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Res Ther (2015) 0.92
Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther (2012) 0.90
Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int (2007) 0.85
Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient! Auto Immun Highlights (2012) 0.83
Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. BMC Res Notes (2009) 0.82
Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease? Rheumatol Int (2014) 0.81
Changes in proliferation kinetics of T cells: a new predictive cellular biomarkers for early rheumatoid arthritis? J Clin Immunol (2012) 0.77
Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review. J Med Life (2013) 0.77
Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis. Clin Rheumatol (2010) 0.77
Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis. Rheumatology (Oxford) (2016) 0.76
The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases. Biomark Insights (2007) 0.75
The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study. Eur J Rheumatol (2014) 0.75
Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics. PLoS One (2015) 0.75
Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity. Med J Islam Repub Iran (2014) 0.75
Is osteoporosis an autoimmune mediated disorder? Bone Rep (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum (2003) 10.65
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004) 7.79
Psoriatic arthritis. Semin Arthritis Rheum (1973) 6.08
Anti-keratin antibodies in rheumatoid arthritis. Br Med J (1979) 3.33
The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol (1999) 3.22
A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther (2004) 2.72
Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis (2003) 2.33
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum (2004) 2.14
Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol (1994) 2.13
Reporting of precision of estimates for diagnostic accuracy: a review. BMJ (1999) 2.09
Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum (1999) 1.77
Clinical assessment of the 1987 American College of Rheumatology criteria for rheumatoid arthritis. Scand J Rheumatol (1996) 1.70
High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol (2003) 1.61
Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis (2004) 1.46
Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (2001) 1.34
Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis (2004) 1.19
Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) (1999) 1.17
Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med (2003) 1.13
Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum (2002) 1.12
A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis--'DIP or not DIP revisited'. Rheumatology (Oxford) (2003) 1.08
Absence of citrulline-specific autoantibodies in animal models of autoimmunity. Arthritis Rheum (2004) 1.00
Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis (2005) 0.97
Development of diagnostic criteria for psoriatic arthritis: methods and process. Curr Rheumatol Rep (2004) 0.93
Rheumatoid arthritis or psoriatic symmetric polyarthritis? A difficult differential diagnosis. Clin Exp Rheumatol (2002) 0.89
Subsets in psoriatic arthritis formed by cluster analysis. Clin Rheumatol (2001) 0.87
Relationship of psoriatic arthritis with the other spondyloarthropathies. Curr Opin Rheumatol (2004) 0.86
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum (2001) 2.96
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis (2003) 2.48
Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 2.37
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol (1999) 2.21
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis (2004) 2.18
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology (1989) 2.06
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) (2005) 2.05
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol (1995) 1.99
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann Rheum Dis (1973) 1.65
Histopathology of intestinal inflammation related to reactive arthritis. Gut (1987) 1.64
Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol (1988) 1.55
Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) (1999) 1.51
The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol (1995) 1.51
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis (2000) 1.47
Serum levels of IgG, IgM, and IgA in rheumatoid arthritis. Ann Rheum Dis (1968) 1.45
Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol (1991) 1.45
The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol (1995) 1.44
Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection. Acta Clin Belg (2014) 1.43
Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clin Exp Rheumatol (1997) 1.42
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet (2000) 1.42
A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol (1999) 1.40
Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum (2000) 1.39
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol (2000) 1.37
Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol (1999) 1.36
Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis (2010) 1.34
Characterisation of human knee meniscus cell phenotype. Osteoarthritis Cartilage (2005) 1.34
Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis (2008) 1.32
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis (2003) 1.31
Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol (1999) 1.31
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis (2003) 1.31
Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis (2005) 1.30
Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis (1999) 1.30
Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) (1999) 1.28
A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford) (2002) 1.27
Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis (2012) 1.24
Rheumatoid nodules: differential diagnosis and immunohistological findings. Ann Rheum Dis (1993) 1.23
HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol (1985) 1.23
Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. Ann Rheum Dis (2008) 1.22
Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology (1996) 1.22
Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Arthritis Rheum (1996) 1.21
Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) (2006) 1.20
Evaluation of T cell subsets with monoclonal antibodies in patients with rheumatoid arthritis. J Rheumatol (1982) 1.19
Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis (2008) 1.19
Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) (2005) 1.18
The antiperinuclear factor. Clin Exp Rheumatol (1991) 1.18
Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab (2007) 1.18
Subclinical involvement of the gut in undifferentiated spondylarthropathies. Clin Exp Rheumatol (1990) 1.16
Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol (1990) 1.16
A prospective study of patients with spondyloarthropathy with special reference to HLA-B27 and to gut histology. J Rheumatol (1993) 1.15
The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum (2001) 1.15
Letter: Levamisole in rheumatoid arthritis. Lancet (1976) 1.15
The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol (1988) 1.15